This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Monday's Health Winners & Losers

AngioDynamics (ANGO - Get Report) said a company it's set to acquire received regulatory clearance for a technology used in the surgical removal of certain types of body tissue. Shares of AngioDynamics edged up 0.4% to $22.10.

The Food and Drug Administration granted Oncobionic approval to market irreversible electroporation technology, which uses needles and image guidance to target cells. The process is similar to existing thermal ablation technologies, but instead of "cooking" or "freezing" the targeted tissue, irreversible electroporation disrupts the cell membrane, thereby destroying the targeted cells.

The impaired cells are then left in the body to be removed by the immune system.

AngioDynamics has announced plans to buy Oncobionic for $5 million in cash, plus an additional $20 million to be paid over two years, pending the achievement of certain milestones. AngioDynamics expects to market a product using irreversible electroporation technology in mid-2008.

The FDA approval "is an important step in achieving our goal of becoming the world leader in image-guided focal tumor therapy," said Eamonn Hobbs, president and chief executive of AngioDynamics.

AngioDynamics also reiterated its expectation that research and development expenses in 2007 will be 8.3% of sales.

Medical-imaging software developer Medicsight (MGT - Get Report) was lower despite getting U.S. clearance for a software tool used to detect colorectal polyps.

The company's ColonCAR technology will help radiologists locate and measure polyps, which are abnormal growths that can lead to cancer. Once suspected polyps are found, the software can determine shape and features and automatically measure diameter and volume.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ANGO $10.02 -0.60%
BSX $16.87 4.98%
MGT $0.24 -7.34%
NXTM $17.67 2.20%
MNKD $0.97 11.07%


Chart of I:DJI
DOW 16,014.38 -12.67 -0.08%
S&P 500 1,852.21 -1.23 -0.07%
NASDAQ 4,268.7630 -14.99 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs